The once-daily oral pill zasocitinib cleared psoriasis lesions at the body's toughest treatment sites — the scalp, palms, soles and nails — according to new data covered by AJMC.

These anatomical regions long have frustrated dermatologists. Thick keratin on palms and soles blunts topical penetration, scalp hair interferes with application adherence, and nail disease responds slowly even to systemic therapy. Patients with involvement at these sites often report the greatest impairment in quality of life, independent of total body surface area.

Zasocitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor, a mechanism that has already reshaped the oral treatment paradigm for moderate-to-severe plaque psoriasis following the approval of deucravacitinib. By blocking TYK2-mediated signaling downstream of IL-23 and IL-12, the drug class targets key psoriasis pathways without the broad immunosuppression associated with earlier oral agents such as methotrexate and apremilast.

The new findings focus on difficult-to-treat site clearance with once-daily dosing. Headline data in the psoriasis field typically center on PASI 75, PASI 90 and PASI 100 response rates at primary endpoints of 12 or 16 weeks; site-specific analyses like these give clinicians a more granular picture of how an agent performs where patients feel their disease most.

For dermatology practices, an effective oral option at these sites carries practical weight. Difficult-site involvement frequently drives biologic escalation, and a convenient once-daily pill that reaches scalp, palmoplantar and nail disease could delay or avoid injectable therapy for a subset of patients. It also matters for adherence: oral therapy removes the injection burden and cold-chain constraints that complicate biolic treatment in some practice settings.

Cardiometabolic comorbidity adds another dimension. Patients with moderate-to-severe psoriasis carry elevated cardiovascular risk, and oral therapies without systemic immunosuppression may fit complex regimens more easily. Selective TYK2 inhibition was designed to avoid JAK1-JAK3 inhibition, aiming to reduce the class-wide safety concerns that have constrained conventional JAK inhibitors.

Approval decisions will hinge on the full pivotal dataset — efficacy endpoints, safety over longer treatment windows, and comparisons against established orals and biologics. Payers will scrutinize placement on formulary tiers, given the crowded psoriasis market already containing an approved TYK2 inhibitor.

Dermatologists should watch for full study results, labeling details and real-world data on durability at difficult sites as zasocitinib advances through regulatory review.